Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Update on shareholder letter.....

"In any event, I do believe that best efforts are being made by management in this regard, under rather difficult circumstances."

While I doubt PTSC's management is loafing, I'm wondering why you characterized PTSC's situation as "rather difficult". I'm not trying to start an argument, but I do not agree with that assessment based on what we know.

Obviously the NDA limits what can be said about the settlements, but there is so much more that can be addressed in a shareholder letter and with over a month having passed since the settlements, if the "difficulty" in crafting this letter hasn't yet been overcome, then I would have serious concerns about PTSC's marketing/PR capabilities.

Having to craft & get such a letter approved for release within days of the settlement might be characterized as "difficult", but five weeks to accomplish such a task is far from difficult. If anything, with at least 11 new licenses signed since the last financial data date, and with the major litigation effort behind them, the business environment PTSC is operating should be much less "difficult" than it was in the previous 6 months when we received multiple share holder letters, IMO.

Share
New Message
Please login to post a reply